The DOI matches its Crossref record.
Steroid-Refractory Acute GVHD: Predictors and Outcomes
Open accessAbstract
Patients with steroid-resistant acute graft versus host disease (aGVHD) have a dismal prognosis, with mortality rates in excess of 90%. We sought to identify a subgroup of patients less likely to benefit from initial therapy with corticosteroids as well as the impact of response on day 14 on outcome. Retrospective evaluation was performed of patients with biopsy-proven aGVHD treated with corticosteroids after allogeneic HSCT at M.D. Anderson Cancer Center from 1998 through 2002 (). Overall response to first-line therapy on day 14 was 56%. Grade III-IV aGVHD and hyperacute GVHD were the most significant factors predicting failure. Patients who fail to respond to steroids by day 14 should be considered for clinical trials. Severity of aGVHD, hyperacute GVHD, and sex mismatch could be integrated into prognostic scoring systems which may allow for pretreatment identification of patients unlikely to benefit from standard therapy with corticosteroids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
Zeiser, R., von Bubnoff, N., Butler, J., Mohty, M., Niederwieser, D., Or, R., Szer, J., Wagner, E. M., Zuckerman, T., Mahuzier, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917635 · Cited by 881
Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S. K., Spoerl, S., Ditschkowski, M., Ecsedi, M., Sockel, K., et al. (2015) · Leukemia · doi:10.1038/leu.2015.212 · Cited by 539
ST2 as a Marker for Risk of Therapy-Resistant Graft-versus-Host Disease and Death
Vander Lugt, M. T., Braun, T. M., Hanash, S., Ritz, J., Ho, V. T., Antin, J. H., Zhang, Q., Wong, C.-H., Wang, H., Chin, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213299 · Cited by 405
Self-citationActivity of therapeutic JAK 1/2 blockade in graft-versus-host disease
Spoerl, S., Mathew, N. R., Bscheider, M., Schmitt-Graeff, A., Chen, S., Mueller, T., Verbeek, M., Fischer, J., Otten, V., Schmickl, M., et al. (2014) · Blood · doi:10.1182/blood-2013-12-543736 · Cited by 401
Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress
Wu, X., Jiang, J., Gu, Z., Zhang, J., Chen, Y., & Liu, X. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01855-9 · Cited by 343
Metadata
- Authors
- Westin, J. R., Saliba, R. M., De Lima, M., Alousi, A., Hosing, C., Qazilbash, M. H., Khouri, I. F., Shpall, E. J., Anderlini, P., Rondon, G., Andersson, B. S., Champlin, R., & Couriel, D. R.
- Venue
- Advances in Hematology
- Publisher
- Wiley
- Published
- 2011
- Volume
- 2011
- Pages
- 1-8
- ISSN
- 1687-9104 (ISSN-L)
- 1687-9112
- OpenAlex
- W2049460956
- Cited by
- 217
- References
- 0
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Steroid-Refractory Acute GVHD: Predictors and Outcomes. https://app.cochat.ai/papers/10.1155/2011/601953
- The paper
- Westin, J. R., Saliba, R. M., De Lima, M., Alousi, A., Hosing, C., Qazilbash, M. H., Khouri, I. F., Shpall, E. J., Anderlini, P., Rondon, G., Andersson, B. S., Champlin, R., & Couriel, D. R. (2011). Steroid-Refractory Acute GVHD: Predictors and Outcomes. Advances in Hematology. https://doi.org/10.1155/2011/601953
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.